Phenprocoumon-induced hepatitis as an immunologically mediated drug allergic complication of antithrombotic therapy

Alexandra Dorn-Beineke; Abdul-Wahab Hassan; Joachim Bräutigam; Ralf Hildenbrand; Carl-Erik Dempfle; Matthias Schwab

doi:10.1055/s-0037-1613425

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2003; 90(06): 1210-1213
DOI: 10.1055/s-0037-1613425

Case Report

Schattauer GmbH

Phenprocoumon-induced hepatitis as an immunologically mediated drug allergic complication of antithrombotic therapy

Authors

Alexandra Dorn-Beineke
Abdul-Wahab Hassan
Joachim Bräutigam
Ralf Hildenbrand
Carl-Erik Dempfle
Matthias Schwab

Abstract

Full Text

References

References
1 Lopez-Cabrera M, Santis AG, Fernandez-Ruiz E. et al. Molecular cloning, expression, and chromosomal localisation of the human earliest lymphocyte activation antigen AIM/ CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors. J Exp Med 1993; 178: 537-47.
2 Ziegler SF, Ramsdell F, Alderson MR. The activation antigen CD69. Stem Cells 1994; 12: 456-65.
3 Haustein KN. Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocoumon. Semin Thromb Hemost 1999; 25: 5-11.
4 Hirtz J, Le Roux Y, Jaouen A. et al. Clinical pharmacology studies with acenocoumarol. Int J Clin Pharmacol Biopharm 1979; 17: 361-5.
5 Loebstein R, Yonath H, Peleg D. et al. Interindividual variability in sensitivity to warfarin – nature or nurture?. Clin Pharmacol Ther 2001; 70: 159-64.
6 He M, Korzekwa KR, Jones JP. et al. Structural forms of phenprocoumon and war-farin that are metabolized at the active site of CYP2C9. Arch Biochem Biophys 1999; 372: 16-28.
7 Rettie AE, Koop DR, Haining RL. CYP2C. In: Metabolic drug interactions. Levy, Thummel, Trager, Hansten, Eichelbaum, ed Philadelphia Lippincott Williams &: Wilkins; 2000: 75-86.
8 Cox D, O’Kennedy R, Thornes RD. The rarity of liver toxicity in patients treated with coumarin (1, 2-benzopyrone). Human Toxicol 1989; 8: 501-6.
9 Casley-Smith JR, Casley-Smith JR. Frequency of coumarin hepatotoxicity. Med J Aust 1995; 162: 391.
10 Ciorciaro C, Hartmann K, Stoller R. et al. Leberschäden durch Coumarin-Antikoagulantien: Erfahrungen der IKS und der SANZ. Schweiz Med Wochenschr 1996; 126: 2109-13.
11 De Man RA. Phenprocoumon-induced liver failure. Neth J Med 1993; 43: 91
12 Höhler T, Schnütgen M, Helmreich-Becker I. et al. Drug-induced hepatitis: a rare complication of oral anticoagulants. J Hepatol 1994; 21: 447-9.
13 Ehrenforth S, Scharrer I, Herrmann G. Phenprocoumon-induzierte nekrotisierende Hepatitis. Dtsch Med Wschr 1995; 120: 1529-30.
14 Ehrenforth S, Schenk JF, Scharrer I. Liver damage induced by coumarin anticoagulants. Semin Throm Hemost 1999; 25: 79-83.
15 Mix H, Wagner S, Böker K. et al. Subacute liver failure induced by phenprocoumon treatment. Digestion 1999; 60: 579-82.
16 Capoferri M, Realini S, Balestra B. Akute nekrotisierende Hepatitis: eine ungewöhnliche Nebenwirkung oraler Antikoagulation. Praxis 2000; 89: 929-32.
17 Hinrichsen H, Lüttges J, Klöppel G. et al. Idiosyncratic drug allergic phenprocoumon-induced hepatitis with subacute liver failure initially misdiagnosed as autoimmune hepatitis. Scand J Gastroenterol 2001; 7: 78017
18 Schneider ARJ, Hartmann D, Arnold JC. et al. Phenprocoumon-assoziierte nekrotisierende Hepatitis. Dtsch Med Wschr 2001; 126: 457-9.
19 Mardinary M, Brown MR, Fleisher TA. Measurement of T-cell CD69 expression: a rapid and efficient means to assess mitogen or antigen-induced proliferative capacity in normals. Cytometry 1996; 26: 305-10.
20 Caruso A, Licenziati S, Corulli M. et al. Flow cytometric analysis of activation markers on stimulated T-cells and their correlation with cell proliferation. Cytometry 1997; 27: 71-6.